Leukocare receives VC financing; Mushroom inhalers to debut soon?;

> Germany's Leukocare announced a financing led by LifeCare Partners in support of its Stabilizing and Protecting Solutions offerings to enhance the thermal stability and shelf life of biologics and vaccines. More

> Celine Park, a student at the Royal College of Art, says so-called fungal inhalers could someday be used to administer vaccines by attaching weakened forms a of virus to fungal spores. "Mold spores are very easy to transport to our lungs," she said, adding, "It can easily transmit to surrounding people so they can easily get herd immunity as well--just like flu or pneumonia." More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.